A Phase II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII Deficiency

Official title

An Open-Label, Multicenter, Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of SR604 Injection in Patients With Congenital Coagulation Factor VII Deficiency

Overview

This is an open-label, multicenter, exploratory Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of SR604 Injection in patients with congenital coagulation Factor VII deficiency.

Interventions

• Drug SR604
  SR604 will be administered as SC injection.

Primary outcome measures

• Treated overall Annualized Bleeding Rate (ABR) [Time frame: Through 28 weeks of treatment.]

Secondary outcome measures (8)

• Treated spontaneous annualized bleeding rate [Time frame: over 28 weeks of treatment]
• Treated overall annualized joint bleeding rate [Time frame: over 28 weeks of treatment]
• Overall annualized bleeding rate including treated and untreated bleeding events [Time frame: over 28 weeks of treatment,]
• Annualized menorrhagia bleeding rate (menstruating females only) [Time frame: over 28 weeks of treatment]
• Change in PBAC score (menstruating females only); [Time frame: From baseline over 28 weeks of treatment]
• Change in EQ-5D-5L health index score [Time frame: From pre-treatment over 28 weeks of treatment]
• Change in EQ-VAS score [Time frame: From baseline over 28 weeks of treatment;]
• Subject overall satisfaction score with treatment efficacy [Time frame: over 28 weeks of treatment]

Eligibility criteria

Inclusion criteria

• Age ≥12 years and ≤65 years at the time of signing the informed consent form; both genders eligible;
• Clinically diagnosed with congenital coagulation Factor VII deficiency, with historical or screening FVII activity <10%, and ≥2 treated new-onset bleeding events within 3 months prior to enrollment;
• No active bleeding symptoms prior to first administration of SR604 Injection;
• The subject and/or legal representative and impartial witness have signed the informed consent form, indicating voluntary agreement to participate in this trial, to provide biological samples for testing as required by the protocol, and to comply with the planned study visits;
• Female subjects (post-menarche) must have a negative serum pregnancy test (HCG) during the screening period; subjects with childbearing potential (females post-menarche or males post-spermarche) must agree to use highly effective contraceptive measures throughout the study period.

Exclusion criteria

• Known history of hypersensitivity to the study drug formulation or any of its components;
• Intolerance to subcutaneous injection or other local skin abnormalities or dermatoses that may affect drug administration or safety assessment;
• Meeting any one of the following criteria during screening:

• Hemoglobin <60 g/L;
• Platelet count <100×10⁹/L;
• Abnormal hepatic or renal function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.5× upper limit of normal (ULN), or total bilirubin ≥1.5× ULN; or serum creatinine (Cr) ≥1.5× ULN;
• Positive for anti-human immunodeficiency virus (HIV) antibodies.
• Any bleeding disorder other than congenital Factor VII deficiency, or other conditions causing significantly abnormal coagulation parameters (e.g., hemophilia A or B, von Willebrand disease, platelet disorders, vitamin K deficiency, etc.);
• Protein C deficiency or Protein S deficiency;
• History of thrombosis, family history of thrombosis, or history of thrombophilia;
• Intracranial hemorrhage within 2 years prior to signing the informed consent form;
• Severe cardiac disease, such as unstable angina, congestive heart failure (New York Heart Association class ≥III), serious arrhythmia (QTc interval >450 ms, corrected by Fridericia formula), uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg), etc.;
• Female patients with menstrual abnormalities caused by organic gynecological conditions (e.g., uterine fibroids, endometriosis, adenomyosis, etc.);
• Received Factor VII-containing products within 48 hours prior to first administration of SR604 Injection; received whole blood or plasma transfusion within 2 weeks prior to first administration of SR604 Injection;
• Used any anticoagulants, antifibrinolytics, or agents affecting platelet function (including chemical drugs, biological products, or traditional Chinese medicine), including aspirin, within 1 week prior to screening, or required use of such agents during the treatment period;
• Underwent major surgery (defined as Grade III or IV surgery) within 1 month prior to signing the informed consent form, or planned to undergo surgery during the study period;
• Enrolled in other clinical trials within 1 month prior to signing the informed consent form;
• Miscarriage or pregnancy termination within 3 months prior to signing the informed consent form; pregnant or breastfeeding women;
• Mental illness or significant psychiatric disorder, or incapacity or lack of cognitive ability due to other causes;
• Other conditions deemed by the investigator to be unsuitable for enrollment, such as alcoholism, anticipated poor subject compliance preventing completion of dosing and study follow-up, poorly controlled comorbid chronic diseases, or serious systemic diseases.

\-

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

China · 1 center

• Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences — Tianjin

Identifiers

NCT: NCT07711158 · LS-SR604-VII-II01

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗